216 related articles for article (PubMed ID: 3591711)
1. Electrocardiographic and electrophysiologic effects of pirmenol in ventricular tachycardia.
Estes NA; Gold R; Cameron J; Haffajee C; Marshall M; Mack K; Salem DN
Am J Cardiol; 1987 Jun; 59(16):20H-26H. PubMed ID: 3591711
[TBL] [Abstract][Full Text] [Related]
2. The efficacy, electrophysiologic and electrocardiographic effects of intravenous pirmenol, a new class I antiarrhythmic agent, in patients with ventricular tachycardia: comparison with procainamide.
Gold RL; Frumin H; Haffajee CI; Kerin NZ; Jarandilla R
Pacing Clin Electrophysiol; 1988 Mar; 11(3):308-14. PubMed ID: 2452418
[TBL] [Abstract][Full Text] [Related]
3. Electrophysiologic evaluation of pirmenol for sustained ventricular tachycardia secondary to coronary artery disease.
Easley AR; Mann DE; Reiter MJ; Sakun V; Sullivan SM; Magro SA; Luck JC; Wyndham CR
Am J Cardiol; 1986 Jul; 58(1):86-9. PubMed ID: 3728337
[TBL] [Abstract][Full Text] [Related]
4. Electrophysiology and antiarrhythmic efficacy of intravenous pirmenol in patients with sustained ventricular tachyarrhythmias.
Liem LB; Clay DA; Franz MR; Swerdlow CD
Am Heart J; 1987 Jun; 113(6):1390-6. PubMed ID: 3591608
[TBL] [Abstract][Full Text] [Related]
5. Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia.
Platia EV; Estes M; Heine DL; Griffith LS; Garan H; Ruskin JN; Reid PR
Am J Cardiol; 1985 Apr; 55(8):956-62. PubMed ID: 3984883
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the electrophysiologic effects of intravenous and oral lorcainide in patients with recurrent ventricular tachycardia.
Echt DS; Mitchell LB; Kates RE; Winkle RA
Circulation; 1983 Aug; 68(2):392-9. PubMed ID: 6861314
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of pirmenol and procainamide in a drug-resistant population with ventricular tachycardia.
Miura DS; Schwartz J; Laux B; Wynn J; Keefe D; Somberg JC
J Clin Pharmacol; 1987 Jul; 27(7):481-6. PubMed ID: 3654999
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy of oral pirmenol in suppressing ventricular premature depolarizations.
de Buitleir M; Crevey BJ; Johnson T; Kou WH; Nelson SD; Schmaltz S; Morady F
Am Heart J; 1988 Aug; 116(2 Pt 1):379-84. PubMed ID: 2456681
[TBL] [Abstract][Full Text] [Related]
9. Acute electrophysiologic effects of pirmenol in normal subjects and in patients with Wolff-Parkinson-White syndrome.
Brown JE; Yee R; Klein GJ
Am J Cardiol; 1986 Apr; 57(10):775-81. PubMed ID: 3962864
[TBL] [Abstract][Full Text] [Related]
10. Clinical electrophysiology, efficacy and safety of chronic oral cibenzoline therapy in refractory ventricular tachycardia.
Rothbart ST; Saksena S
Am J Cardiol; 1986 Apr; 57(11):941-6. PubMed ID: 3515898
[TBL] [Abstract][Full Text] [Related]
11. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans.
Sager PT; Nademanee K; Antimisiaris M; Pacifico A; Pruitt C; Godfrey R; Singh BN
Circulation; 1993 Sep; 88(3):1072-82. PubMed ID: 8353869
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of nadolol alone or in combination with a type IA antiarrhythmic drug in sustained ventricular tachycardia: a prospective study.
Munsif AN; Saksena S
Pacing Clin Electrophysiol; 1989 Nov; 12(11):1816-26. PubMed ID: 2478982
[TBL] [Abstract][Full Text] [Related]
13. Pirmenol: an antiarrhythmic drug with unique electrocardiographic features--a double-blind placebo-controlled comparison with quinidine.
Salerno DM; Fifield J; Farmer C; Hodges M
Clin Cardiol; 1991 Jan; 14(1):25-32. PubMed ID: 2019027
[TBL] [Abstract][Full Text] [Related]
14. Effects of pirmenol on electrical induction of sustained ventricular tachycardia in a seven-day-old canine myocardial infarction.
Nitta J; Nogami A; Aonuma K; Akimoto H; Chung YH; Takahashi A; Iesaka Y; Marumo F; Hiraoka M
J Cardiovasc Pharmacol; 1991 Jan; 17(1):54-60. PubMed ID: 1708056
[TBL] [Abstract][Full Text] [Related]
15. Electrophysiologic effects of intravenous E-4031, a novel class III antiarrhythmic agent, in patients with supraventricular tachyarrhythmias.
Fujiki A; Tani M; Mizumaki K; Shimono M; Inoue H
J Cardiovasc Pharmacol; 1994 Mar; 23(3):374-8. PubMed ID: 7515979
[TBL] [Abstract][Full Text] [Related]
16. Lorcainide for the treatment of refractory ventricular tachycardia: clinical and electrophysiologic results.
Hanyok JJ; Kluger J; Chow MS; Fieldman A
J Clin Pharmacol; 1987 Apr; 27(4):278-82. PubMed ID: 3680584
[TBL] [Abstract][Full Text] [Related]
17. Clinical effects and pharmacokinetics of a single oral dose of pirmenol hydrochloride.
Atarashi H; Kuruma A; Ino T; Hirayama Y; Saitoh H; Hayakawa H
J Cardiovasc Pharmacol; 1996 Apr; 27(4):556-62. PubMed ID: 8847873
[TBL] [Abstract][Full Text] [Related]
18. Clinical and electrophysiologic assessment of oral flecainide acetate for recurrent ventricular tachycardia: evidence for exacerbation of electrical instability.
Oetgen WJ; Tibbits PA; Abt ME; Goldstein RE
Am J Cardiol; 1983 Oct; 52(7):746-50. PubMed ID: 6624666
[TBL] [Abstract][Full Text] [Related]
19. The relation of the kinetics of pirmenol to its antiarrhythmic efficacy.
Johnson BF; Haffajee CI; Woodman T; Sloan KL
J Clin Pharmacol; 1988 May; 28(5):401-5. PubMed ID: 3392237
[TBL] [Abstract][Full Text] [Related]
20. Limited role of intravenous propafenone hydrochloride in the treatment of sustained ventricular tachycardia: electrophysiologic effects and results of programmed ventricular stimulation.
Doherty JU; Waxman HL; Kienzle MG; Cassidy DM; Marchlinski FE; Buxton AE; Josephson ME
J Am Coll Cardiol; 1984 Aug; 4(2):378-81. PubMed ID: 6736479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
